Phaseline

Targets › CD34

CD34 (Hematopoietic progenitor cell antigen CD34): drug programs, companies and trials

9 programs from 9 companies in 10 trials: 10 Phase 1; Oncology, Genitourinary, Other; next expected readout Dec 2026.

Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. (UniProt, P28906)

Open in Phaseline: the race on CD34, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Paul Szabolcsautologous CD34-selected peripheral blood stem cells transplant
CD34-selected hematopoietic stem cell transplantation
CD34Phase 1Crohn's DiseaseDec 2026
Jeffrey Veale, MDCD34+ and CD3+ hematopoietic stem/progenitor cells
Donor-derived blood stem and T cells for facilitating mixed chimerism and immune tolerance
CD34, CD3EPhase 1Renal Transplant RejectionMay 2027
Francisco Hernández OliverosCD34+ enriched, naïve T cell-depleted hematopoietic graft supplemented with memo
Hematopoietic stem cell transplantation with selective lymphocyte composition to promote i
CD34Phase 1Solid Organ Transplant ComplicationsJun 2028
Stanford UniversityDonor Hematopoietic Stem Cells and Recipient Tregs
Donor CD34+ hematopoietic stem cells combined with recipient regulatory T cells to facilit
CD34, IL2RAPhase 1Glioma of Spinal Cord; Living Donor Kidney TransplantationJul 2028
Columbia UniversityCD34+ stem cells from donor bone marrow
Infusion of CD34+ hematopoietic stem cells to promote mixed chimerism and reduce rejection
CD34Phase 1Intestinal TransplantationDec 2028
University of Alabama at BirminghamCD34 selected hematopoietic stem cells
CD34+ cell selection and enrichment from hematopoietic stem cell graft
CD34Phase 1AMLOct 2029
Diane GeorgeCliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device)
CD34+ cell selection device for T-cell depletion from peripheral blood stem cell transplan
CD34, CD3Phase 1Bone Marrow Failure SyndromeFeb 2030
University of FloridaexHSC (ex vivo expanded CD34+ hematopoietic stem cells)
Ex vivo expanded CD34+ hematopoietic stem cells
CD34Phase 1Recurrent High-grade GliomaDec 2030
Melody SmithOrca-T
Purified donor-derived regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells
CD34Phase 1Lymphoid LeukemiaDec 2045

Conditions

Bone Marrow Failure Syndrome (1) Lymphoid Leukemia (1) Renal Transplant Rejection (1) Crohn's Disease (1) AML (1) Glioma of Spinal Cord (1) Living Donor Kidney Transplantation (1) Solid Organ Transplant Complications (1) Recurrent High-grade Glioma (1) Intestinal Transplantation (1)

Modalities

other (5), mixed (3), protein or peptide (1)

Companies

Diane George (1) Melody Smith (1) Jeffrey Veale, MD (1) Paul Szabolcs (1) University of Alabama at Birmingham (1) Stanford University (1) Francisco Hernández Oliveros (1) University of Florida (1) Columbia University (1)

Related targets

CD3 (1) CD3E (1) IL2RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.